GENMAB AS SP.ADR/1/10DK 1 (GE91) - Total Assets
Based on the latest financial reports, GENMAB AS SP.ADR/1/10DK 1 (GE91) holds total assets worth €12.87 Billion EUR (≈ $15.05 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore GENMAB AS SP.ADR/1/10DK 1 strategic investment ratio to see how much of total assets are deployed in long-term investments.
GENMAB AS SP.ADR/1/10DK 1 - Total Assets Trend (2021–2025)
This chart illustrates how GENMAB AS SP.ADR/1/10DK 1's total assets have evolved over time, based on quarterly financial data. Check GE91 asset resilience ratio to evaluate the company's liquid asset resilience ratio.
GENMAB AS SP.ADR/1/10DK 1 - Asset Composition Analysis
Current Asset Composition (December 2025)
GENMAB AS SP.ADR/1/10DK 1's total assets of €12.87 Billion consist of 22.4% current assets and 77.6% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 13.3% |
| Accounts Receivable | €1.11 Billion | 8.6% |
| Inventory | €18.00 Million | 0.1% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €9.12 Billion | 70.9% |
| Goodwill | €355.00 Million | 2.8% |
Asset Composition Trend (2021–2025)
This chart illustrates how GENMAB AS SP.ADR/1/10DK 1's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see GE91 market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: GENMAB AS SP.ADR/1/10DK 1's current assets represent 22.4% of total assets in 2025, a decrease from 92.3% in 2021.
- Cash Position: Cash and equivalents constituted 13.3% of total assets in 2025, down from 36.4% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 72.0% of total assets, an increase from 1.0% in 2021.
- Asset Diversification: The largest asset category is intangible assets at 70.9% of total assets.
GENMAB AS SP.ADR/1/10DK 1 Competitors by Total Assets
Key competitors of GENMAB AS SP.ADR/1/10DK 1 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.82 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $146.48 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
|
Hyundai Bioscience Co. Ltd
KQ:048410
|
Korea | ₩130.74 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥772.57 Million |
|
Lifecome Biochemistry Co Ltd
SHE:002868
|
China | CN¥773.72 Million |
GENMAB AS SP.ADR/1/10DK 1 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.02 | 5.24 | 5.17 |
| Quick Ratio | 2.01 | 5.23 | 5.15 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €1.46 Billion | €3.16 Billion | €2.86 Billion |
GENMAB AS SP.ADR/1/10DK 1 - Advanced Valuation Insights
This section examines the relationship between GENMAB AS SP.ADR/1/10DK 1's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.84 |
| Latest Market Cap to Assets Ratio | 1.17 |
| Asset Growth Rate (YoY) | 101.4% |
| Total Assets | €12.87 Billion |
| Market Capitalization | $15.06 Billion USD |
Valuation Analysis
Above Book Valuation: The market values GENMAB AS SP.ADR/1/10DK 1's assets above their book value (1.17x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: GENMAB AS SP.ADR/1/10DK 1's assets grew by 101.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for GENMAB AS SP.ADR/1/10DK 1 (2021–2025)
The table below shows the annual total assets of GENMAB AS SP.ADR/1/10DK 1 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €12.87 Billion ≈ $15.05 Billion |
+101.41% |
| 2024-12-31 | €6.39 Billion ≈ $7.47 Billion |
+21.99% |
| 2023-12-31 | €5.24 Billion ≈ $6.13 Billion |
+20.86% |
| 2022-12-31 | €4.33 Billion ≈ $5.07 Billion |
+15.63% |
| 2021-12-31 | €3.75 Billion ≈ $4.38 Billion |
-- |
About GENMAB AS SP.ADR/1/10DK 1
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervi… Read more